Bradley Elizabeth A, Sloan Jeff A, Novotny Paul J, Garrity James A, Woog John J, West Sheila K
Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Ophthalmology. 2006 Aug;113(8):1450-4. doi: 10.1016/j.ophtha.2006.02.060. Epub 2006 Jun 12.
To determine the potential suitability of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) for measuring health-related quality of life (HRQL) in patients with Graves' ophthalmopathy.
Cross-sectional study.
Thirty adult patients with mild to severe Graves' ophthalmopathy.
Participants self-administered the NEI VFQ-25 and completed a semistructured interview to provide feedback about the questionnaire. The percentage of responses at the maximum and minimum value was calculated to assess ceiling and floor effects, respectively, for the 12 subscales of the NEI VFQ-25. The NEI VFQ-25 scores were compared for Graves' ophthalmopathy patients who reported symptomatic diplopia and those who did not report diplopia using univariate and multivariate linear regression models.
The NEI VFQ-25 subscale and composite scores.
Health-related quality of life in those with Graves' ophthalmopathy was moderately impaired, with median composite score of 69. The greatest impairment was measured in the Mental Health (median, 50) and the Role Difficulties (median, 50) subscales. Significant ceiling effects were seen in 7 of the 12 subscales. More than two thirds of Graves' ophthalmopathy patients perceived that the NEI VFQ-25 lacked items relevant to their disease. The NEI VFQ-25 scores were lower for those with diplopia symptoms (composite score, 61) compared with those without diplopia (composite score, 90). Comparing these 2 groups, the largest differences were measured in the Driving and Peripheral Vision subscales.
The NEI VFQ-25 includes many items that are applicable to Graves' ophthalmopathy patients. However, it shows significant ceiling effects in more than half of the subscales and it lacks items on issues that are important to Graves' ophthalmopathy patients, such as altered appearance and ocular discomfort. Efforts to develop an HRQL instrument that adds Graves' ophthalmopathy-specific items to relevant aspects of the NEI VFQ-25 are warranted.
确定25项美国国立眼科研究所视觉功能问卷（NEI VFQ - 25）在测量格雷夫斯眼病患者健康相关生活质量（HRQL）方面的潜在适用性。
横断面研究。
30例轻度至重度格雷夫斯眼病成年患者。
参与者自行填写NEI VFQ - 25，并完成一次半结构化访谈以提供有关该问卷的反馈。计算NEI VFQ - 25的12个分量表在最大值和最小值处的回答百分比以分别评估天花板效应和地板效应。使用单变量和多变量线性回归模型比较报告有症状性复视的格雷夫斯眼病患者和未报告复视的患者的NEI VFQ - 25得分。
NEI VFQ - 25分量表得分和综合得分。
格雷夫斯眼病患者的健康相关生活质量受到中度损害，综合得分中位数为69。在心理健康（中位数为5０）和角色困难（中位数为5０）分量表中观察到最大损害。12个分量表中有7个出现显著的天花板效应。超过三分之二的格雷夫斯眼病患者认为NEI VFQ - 25缺乏与他们疾病相关的条目。有复视症状的患者的NEI VFQ - 25得分（综合得分61）低于无复视症状的患者（综合得分9０）。比较这两组，在驾驶和周边视觉分量表中差异最大。
NEI VFQ - 25包含许多适用于格雷夫斯眼病患者的条目。然而，它在一半以上的分量表中显示出显著的天花板效应，并且缺乏对格雷夫斯眼病患者重要的问题的条目，如外观改变和眼部不适。有必要努力开发一种HRQL工具，在NEI VFQ - 25的相关方面增加格雷夫斯眼病特异性条目。
